 The substantially improved pharmacological profile of GP532 opens new opportunities for broader therapeutic applications of this class of pharmaceuticals BUFFALO, NY ACCESSWIRE April 14, 2021 Genome Protection, Inc. GPI, a joint venture between Cleveland BioLabs, Inc. NASDAQ:CBLI and Everon BioSciences, LLC, an innovative biopharmaceutical company focused on developing medical interventions to prevent and treat aging and age-related diseases, announces a publication in Communications Biology, a journal of Nature portfolio, describing the creation, properties and preclinical validation of efficacy of a new deimmunized and pharmacologically optimized Toll-like receptor 5 TLR5 agonist, named GP532. The article demonstrates potency of GP532 for prophylaxis and treatment of acute radiation syndrome ARS in preclinical models. 